Peter Attia, MD is wrong about Prostate Cancer and PSA

Intellectual Medicine · May 5, 2026 · 16m · transcript

Clear thinking leads to stronger health decisions and better long-term outcomes.

In this episode, Dr. Stephen Petteruti takes a closer look at common guidance around PSA testing and early prostate cancer detection, including viewpoints from Peter Attia, MD. He explains how impressive-sounding statistics can mislead, showing that a 44% relative risk reduction translates to only a 0.34% actual benefit.

He reframes PSA as a monitoring tool. The typical pathway often leads to harm without proven life extension. Evidence from long-term studies shows no meaningful difference in prostate cancer…